Pediatric osteosarcoma

Treatment of the primary tumor with intra-arterial cis-diamminedichloroplatinum-II. Factors demonstrating that a systemic therapeutic effect is also attained

N. Jaffe, P. Pearson, Z. Lamki, S. Wallace, C. H. Carrasco, A. K. Raymond, A. G. Ayala

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Intra-arterial cis-diamminedichloroplatinum-II (CDP) is effective in treating the primary tumor in osteosarcoma. The strategy may be criticized on the grounds that it does not provide therapy for concurrent metastatic disease. We reviewed our experience with the use of intra-arterial CDP. This permitted an opportunity to adduce evidence that a systemic effect to treat established and micrometastases was attained. This may be summarized as follows: 1) Nausea and vomiting occurred during the infusion in almost all patients. 2) Many patients complained of a transient metallic taste and expectorated during and after treatment. 3) Approximately 20% of patients experienced transient hypertension after the second or third course. 4) A reduction in creatinine clearance occurred in practically all patients. 5) Pharmacokinetic studies revealed that with 150 mg/m2 administered intra- arterially over two hours, a steady state was approached in the systemic circulation in two to three hours, attaining a serum CDP level of 3.9 microgram/ml at 120 minutes in the peripheral vein. 6) Auditory deficits developed in the majority of the patients. 7) Hyper-pigmentation developed at sites remote from the primary tumor: Particularly affected were the knuckles of the feet and hands, elbows and knees and areas around the base of the neck. Growth arrest lines in the nail beds of the fingers and toes were also encountered. 8) Finally, responses were noted in seven of eleven patients with established pulmonary metastases. These data are consonant with the premise that intra-arterial CDP, while providing an attack on the primary tumor, achieves systemic tumoricidal drug concentrations. These concentrations cause a variety of side effects and are capable of destroying metastatic disease.

Original languageEnglish
Pages (from-to)128-132
Number of pages5
JournalRegional Cancer Treatment
Volume8
Issue number3-4
Publication statusPublished - 1995

Fingerprint

Therapeutic Uses
Osteosarcoma
Cisplatin
Pediatrics
Neoplasms
Therapeutics
Taste Disorders
Neoplasm Micrometastasis
Pigmentation
Toes
Elbow
Nails
Nausea
Fingers
Vomiting
Foot
Veins
Creatinine
Knee
Neck

Keywords

  • Cis-diamminedichloroplatinum-II
  • Intra-arterial administration achieves a systemic therapeutic effect

ASJC Scopus subject areas

  • Oncology
  • Pharmacology

Cite this

Pediatric osteosarcoma : Treatment of the primary tumor with intra-arterial cis-diamminedichloroplatinum-II. Factors demonstrating that a systemic therapeutic effect is also attained. / Jaffe, N.; Pearson, P.; Lamki, Z.; Wallace, S.; Carrasco, C. H.; Raymond, A. K.; Ayala, A. G.

In: Regional Cancer Treatment, Vol. 8, No. 3-4, 1995, p. 128-132.

Research output: Contribution to journalArticle

@article{b553921721b445d4a575e9c59b1cb466,
title = "Pediatric osteosarcoma: Treatment of the primary tumor with intra-arterial cis-diamminedichloroplatinum-II. Factors demonstrating that a systemic therapeutic effect is also attained",
abstract = "Intra-arterial cis-diamminedichloroplatinum-II (CDP) is effective in treating the primary tumor in osteosarcoma. The strategy may be criticized on the grounds that it does not provide therapy for concurrent metastatic disease. We reviewed our experience with the use of intra-arterial CDP. This permitted an opportunity to adduce evidence that a systemic effect to treat established and micrometastases was attained. This may be summarized as follows: 1) Nausea and vomiting occurred during the infusion in almost all patients. 2) Many patients complained of a transient metallic taste and expectorated during and after treatment. 3) Approximately 20{\%} of patients experienced transient hypertension after the second or third course. 4) A reduction in creatinine clearance occurred in practically all patients. 5) Pharmacokinetic studies revealed that with 150 mg/m2 administered intra- arterially over two hours, a steady state was approached in the systemic circulation in two to three hours, attaining a serum CDP level of 3.9 microgram/ml at 120 minutes in the peripheral vein. 6) Auditory deficits developed in the majority of the patients. 7) Hyper-pigmentation developed at sites remote from the primary tumor: Particularly affected were the knuckles of the feet and hands, elbows and knees and areas around the base of the neck. Growth arrest lines in the nail beds of the fingers and toes were also encountered. 8) Finally, responses were noted in seven of eleven patients with established pulmonary metastases. These data are consonant with the premise that intra-arterial CDP, while providing an attack on the primary tumor, achieves systemic tumoricidal drug concentrations. These concentrations cause a variety of side effects and are capable of destroying metastatic disease.",
keywords = "Cis-diamminedichloroplatinum-II, Intra-arterial administration achieves a systemic therapeutic effect",
author = "N. Jaffe and P. Pearson and Z. Lamki and S. Wallace and Carrasco, {C. H.} and Raymond, {A. K.} and Ayala, {A. G.}",
year = "1995",
language = "English",
volume = "8",
pages = "128--132",
journal = "Regional Cancer Treatment",
issn = "0935-0411",
publisher = "Springer Verlag",
number = "3-4",

}

TY - JOUR

T1 - Pediatric osteosarcoma

T2 - Treatment of the primary tumor with intra-arterial cis-diamminedichloroplatinum-II. Factors demonstrating that a systemic therapeutic effect is also attained

AU - Jaffe, N.

AU - Pearson, P.

AU - Lamki, Z.

AU - Wallace, S.

AU - Carrasco, C. H.

AU - Raymond, A. K.

AU - Ayala, A. G.

PY - 1995

Y1 - 1995

N2 - Intra-arterial cis-diamminedichloroplatinum-II (CDP) is effective in treating the primary tumor in osteosarcoma. The strategy may be criticized on the grounds that it does not provide therapy for concurrent metastatic disease. We reviewed our experience with the use of intra-arterial CDP. This permitted an opportunity to adduce evidence that a systemic effect to treat established and micrometastases was attained. This may be summarized as follows: 1) Nausea and vomiting occurred during the infusion in almost all patients. 2) Many patients complained of a transient metallic taste and expectorated during and after treatment. 3) Approximately 20% of patients experienced transient hypertension after the second or third course. 4) A reduction in creatinine clearance occurred in practically all patients. 5) Pharmacokinetic studies revealed that with 150 mg/m2 administered intra- arterially over two hours, a steady state was approached in the systemic circulation in two to three hours, attaining a serum CDP level of 3.9 microgram/ml at 120 minutes in the peripheral vein. 6) Auditory deficits developed in the majority of the patients. 7) Hyper-pigmentation developed at sites remote from the primary tumor: Particularly affected were the knuckles of the feet and hands, elbows and knees and areas around the base of the neck. Growth arrest lines in the nail beds of the fingers and toes were also encountered. 8) Finally, responses were noted in seven of eleven patients with established pulmonary metastases. These data are consonant with the premise that intra-arterial CDP, while providing an attack on the primary tumor, achieves systemic tumoricidal drug concentrations. These concentrations cause a variety of side effects and are capable of destroying metastatic disease.

AB - Intra-arterial cis-diamminedichloroplatinum-II (CDP) is effective in treating the primary tumor in osteosarcoma. The strategy may be criticized on the grounds that it does not provide therapy for concurrent metastatic disease. We reviewed our experience with the use of intra-arterial CDP. This permitted an opportunity to adduce evidence that a systemic effect to treat established and micrometastases was attained. This may be summarized as follows: 1) Nausea and vomiting occurred during the infusion in almost all patients. 2) Many patients complained of a transient metallic taste and expectorated during and after treatment. 3) Approximately 20% of patients experienced transient hypertension after the second or third course. 4) A reduction in creatinine clearance occurred in practically all patients. 5) Pharmacokinetic studies revealed that with 150 mg/m2 administered intra- arterially over two hours, a steady state was approached in the systemic circulation in two to three hours, attaining a serum CDP level of 3.9 microgram/ml at 120 minutes in the peripheral vein. 6) Auditory deficits developed in the majority of the patients. 7) Hyper-pigmentation developed at sites remote from the primary tumor: Particularly affected were the knuckles of the feet and hands, elbows and knees and areas around the base of the neck. Growth arrest lines in the nail beds of the fingers and toes were also encountered. 8) Finally, responses were noted in seven of eleven patients with established pulmonary metastases. These data are consonant with the premise that intra-arterial CDP, while providing an attack on the primary tumor, achieves systemic tumoricidal drug concentrations. These concentrations cause a variety of side effects and are capable of destroying metastatic disease.

KW - Cis-diamminedichloroplatinum-II

KW - Intra-arterial administration achieves a systemic therapeutic effect

UR - http://www.scopus.com/inward/record.url?scp=0029553783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029553783&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 128

EP - 132

JO - Regional Cancer Treatment

JF - Regional Cancer Treatment

SN - 0935-0411

IS - 3-4

ER -